MiR-548c impairs migration and invasion of endometrial and ovarian cancer cells via downregulation of Twist

Journal of Experimental and Clinical Cancer Research

Volumn 35, Issue 1, 2016, Pages

  Sun, Xiaochun ^a   Cui, Manhua ^a   Zhang, Aichen ^a   Tong, Lingling ^a   Wang, Kun ^a   Li, Kai ^a   Wang, Xue ^a   Sun, Ziqian ^a   Zhang, Hongye ^a  

^a JILIN UNIVERSITY   (China)

Author keywords

EMT; Endometrial cancer; microRNA; miR 548c; Ovarian cancer

Indexed keywords

MICRORNA; MICRORNA 548C; TRANSCRIPTION FACTOR TWIST; UNCLASSIFIED DRUG; 3' UNTRANSLATED REGION; MIRN548 MICRORNA, HUMAN; NUCLEAR PROTEIN; TWIST RELATED PROTEIN 1; TWIST1 PROTEIN, HUMAN;

ADULT; ARTICLE; CANCER PROGNOSIS; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; ENDOMETRIAL CANCER CELL LINE; ENDOMETRIUM CANCER; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; ONCOGENE; OVARIAN CANCER CELL LINE; OVARY CANCER; PRIORITY JOURNAL; SURVIVAL RATE; TWIST GENE; 3' UNTRANSLATED REGION; CELL MOTION; ENDOMETRIUM TUMOR; GENE EXPRESSION REGULATION; GENETICS; OVARY TUMOR; PATHOLOGY; TUMOR CELL LINE; TUMOR INVASION;

3' UNTRANSLATED REGIONS; CELL LINE, TUMOR; CELL MOVEMENT; DOWN-REGULATION; ENDOMETRIAL NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICRORNAS; NEOPLASM INVASIVENESS; NUCLEAR PROTEINS; OVARIAN NEOPLASMS; TWIST-RELATED PROTEIN 1;

EID: 84954126058     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/s13046-016-0288-0     Document Type: Article

References (41)

1. Dong P, Kaneuchi M, Konno Y, Watari H, Sudo S, Sakuragi N. Emerging therapeutic biomarkers in endometrial cancer. Biomed Res Int. 2013;2013:130362.
2. Kim A, Ueda Y, Naka T, Enomoto T. Therapeutic strategies in epithelial ovarian cancer. J Exp Clin Cancer Res. 2012;31:14.
3. Bast Jr RC, Hennessy B, Mills GB. The biology of ovarian cancer: new opportunities for translation. Nat Rev Cancer. 2009;9:415-28.
4. Mehlen P, Puisieux A. Metastasis: a question of life or death. Nat Rev Cancer. 2006;6:449-58.
5. Vergara D, Merlot B, Lucot JP, Collinet P, Vinatier D, Fournier I, et al. Epithelial-mesenchymal transition in ovarian cancer. Cancer Lett. 2010;291:59-66.
6. Kaufhold S, Bonavida B. Central role of Snail1 in the regulation of EMT and resistance in cancer: a target for therapeutic intervention. J Exp Clin Cancer Res. 2014;33:62.
7. Wang WS, Yu SL, Yang XS, Chang SD, Hou JQ. Expression and significance of twist and E-cadherin in ovarian cancer tissues. Asian Pac J Cancer Prev. 2013;14:669-72.
8. Wang WS, Yang XS, Xia M, Jiang HY, Hou JQ. Silencing of twist expression by RNA interference suppresses epithelial-mesenchymal transition, invasion, and metastasis of ovarian cancer. Asian Pac J Cancer Prev. 2012;13:4435-9.
9. Kyo S, Sakaguchi J, Ohno S, Mizumoto Y, Maida Y, Hashimoto M, et al. High Twist expression is involved in infiltrative endometrial cancer and affects patient survival. Hum Pathol. 2006;37:431-8.
10. Yoshida J, Horiuchi A, Kikuchi N, Hayashi A, Osada R, Ohira S, et al. Changes in the expression of E-cadherin repressors, Snail, Slug, SIP1, and Twist, in the development and progression of ovarian carcinoma: the important role of Snail in ovarian tumorigenesis and progression. Med Mol Morphol. 2009;42:82-91.
11. Hosono S, Kajiyama H, Terauchi M, Shibata K, Ino K, Nawa A, et al. Expression of Twist increases the risk for recurrence and for poor survival in epithelial ovarian carcinoma patients. Br J Cancer. 2007;96:314-20.
12. Pencheva N, Tavazoie SF. Control of metastatic progression by microRNA regulatory networks. Nat Cell Biol. 2013;15:546-54.
13. Liu X, Chen X, Yu X, Tao Y, Bode AM, Dong Z, et al. Regulation of microRNAs by epigenetics and their interplay involved in cancer. J Exp Clin Cancer Res. 2013;32:96.
14. Katz B, Tropé CG, Reich R, Davidson B. MicroRNAs in ovarian cancer. Hum Pathol. 2015;46:1245-56.
15. Dong P, Kaneuchi M, Watari H, Sudo S, Sakuragi N. MicroRNA-106b modulates epithelial-mesenchymal transition by targeting TWIST1 in invasive endometrial cancer cell lines. Mol Carcinog. 2014;53:349-59.
16. Bing L, Hong C, Li-Xin S, Wei G. MicroRNA-543 suppresses endometrial cancer oncogenicity via targeting FAK and TWIST1 expression. Arch Gynecol Obstet. 2014;290:533-41.
17. Shirdel EA, Xie W, Mak TW, Jurisica I. NAViGaTing the micronome - using multiple microRNA prediction databases to identify signalling pathway-associated microRNAs. PLoS ONE. 2011;6:e17429.
18. Piriyapongsa J, Jordan IK. A family of human microRNA genes from miniature inverted-repeat transposable elements. PLoS ONE. 2007;2, e203.
19. Hu B, Ying X, Wang J, Piriyapongsa J, Jordan IK, Sheng J, et al. Identification of a tumor-suppressive human-specific microRNA within the FHIT tumor-suppressor gene. Cancer Res. 2014;74:2283-94.
20. Odero-Marah VA, Wang R, Chu G, Zayzafoon M, Xu J, Shi C, et al. Receptor activator of NF-kappaB Ligand (RANKL) expression is associated with epithelial to mesenchymal transition in human prostate cancer cells. Cell Res. 2008;18:858-70.
21. Chiou SH, Wang ML, Chou YT, Chen CJ, Hong CF, Hsieh WJ, et al. Coexpression of Oct4 and Nanog enhances malignancy in lung adenocarcinoma by inducing cancer stem cell-like properties and epithelial-mesenchymal transdifferentiation. Cancer Res. 2010;70:10433-44.
22. Figueira RC, Gomes LR, Neto JS, Silva FC, Silva ID, Sogayar MC. Correlation between MMPs and their inhibitors in breast cancer tumor tissue specimens and in cell lines with different metastatic potential. BMC Cancer. 2009;9:20.
23. Dong P, Kaneuchi M, Watari H, Hamada J, Sudo S, Ju J, et al. MicroRNA-194 inhibits epithelial to mesenchymal transition of endometrial cancer cells by targeting oncogene BMI-1. Mol Cancer. 2011;10:99.
24. Dong P, Karaayvaz M, Jia N, Kaneuchi M, Hamada J, Watari H, et al. Mutant p53 gain-of-function induces epithelial-mesenchymal transition through modulation of the miR-130b-ZEB1 axis. Oncogene. 2013;32:3286-95.
25. Dong PX, Jia N, Xu ZJ, Liu YT, Li DJ, Feng YJ. Silencing of IQGAP1 by shRNA inhibits the invasion of ovarian carcinoma HO-8910PM cells in vitro. J Exp Clin Cancer Res. 2008;27:7.
26. Aguirre-Gamboa R, Trevino V. SurvMicro: assessment of miRNA based prognostic signatures for cancer clinical outcomes by multivariate survival analysis. Bioinformatics. 2014;30:1630-2.
27. Lu TP, Lee CY, Tsai MH, Chiu YC, Hsiao CK, Lai LC, et al. miRSystem: an integrated system for characterizing enriched functions and pathways of microRNA targets. PLoS ONE. 2012;7:e42390.
28. Vesuna F, van Diest P, Chen JH, Raman V. Twist is a transcriptional repressor of E-cadherin gene expression in breast cancer. Biochem Biophys Res Commun. 2008;367:235-41.
29. Alexander NR, Tran NL, Rekapally H, Summers CE, Glackin C, Heimark RLAlexander NR, et al. N-cadherin Gene Expression in Prostate Carcinoma Is Modulated by Integrin-Dependent Nuclear Translocation of Twist1. Cancer Res. 2006;66:3365-9.
30. Singh A, Settleman J. EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene. 2010;29:4741-51.
31. Nakamura M, Kyo S, Zhang B, Zhang X, Mizumoto Y, Takakura M, et al. Prognostic impact of CD133 expression as a tumor-initiating cell marker in endometrial cancer. Hum Pathol. 2010;41:1516-29.
32. Ma L, Lai D, Liu T, Cheng W, Guo L. Cancer stem-like cells can be isolated with drug selection in human ovarian cancer cell line SKOV3. Acta Biochim Biophys Sin (Shanghai). 2010;42:593-602.
33. Zhao XL, Sun T, Che N, Sun D, Zhao N, Dong XY, et al. Promotion of hepatocellular carcinoma metastasis through matrix metalloproteinase activation by epithelial-mesenchymal transition regulator Twist1. J Cell Mol Med. 2011;15:691-700.
34. Brunetti O, Russo A, Scarpa A, Santini D, Reni M, Bittoni A, et al. MicroRNA in pancreatic adenocarcinoma: predictive/prognostic biomarkers or therapeutic targets? Oncotarget. 2015;6:23323-41.
35. Luo G, Chao YL, Tang B, Li BS, Xiao YF, Xie R, et al. miR-149 represses metastasis of hepatocellular carcinoma by targeting actin-regulatory proteins PPM1F. Oncotarget. 2015;6:37808-23.
36. Kang Y, Massagué J. Epithelial-mesenchymal transitions: twist in development and metastasis. Cell. 2004;118:277-9.
37. Khan MA, Chen HC, Zhang D, Fu J. Twist: a molecular target in cancer therapeutics. Tumour Biol. 2013;34:2497-506.
38. Jung HY, Yang J. Unraveling the TWIST between EMT and Cancer Stemness. Cell Stem Cell. 2015;16:1-2.
39. Ma L, Teruya-Feldstein J, Weinberg RA. Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature. 2007;449(7163):682-8.
40. Drasin DJ, Guarnieri AL, Neelakantan D, Kim J, Cabrera JH, Wang CA, et al. TWIST1-Induced miR-424 Reversibly Drives Mesenchymal Programming while Inhibiting Tumor Initiation. Cancer Res. 2015;75(9):1908-21.
41. Boukerroucha M, Josse C, ElGuendi S, Boujemla B, Frères P, Marée R, et al. Evaluation of BRCA1-related molecular features and microRNAs as prognostic factors for triple negative breast cancers. BMC Cancer. 2015;15:755.